Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.
2.

Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).

Yamada Y, Senda M, Naito Y, Tamura M, Watanabe D, Shuto Y, Urita Y.

Diabetes Obes Metab. 2017 Sep;19(9):1252-1259. doi: 10.1111/dom.12945. Epub 2017 Apr 27.

3.
4.

Update on the treatment of type 2 diabetes mellitus.

Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ.

World J Diabetes. 2016 Sep 15;7(17):354-95. doi: 10.4239/wjd.v7.i17.354. Review.

5.

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.

Raccah D, Chou E, Colagiuri S, Gaàl Z, Lavalle F, Mkrtumyan A, Nikonova E, Tentolouris N, Vidal J, Davies M.

Diabetes Metab Res Rev. 2017 Mar;33(3). doi: 10.1002/dmrr.2858. Epub 2016 Oct 13.

6.

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.

Gough SC, Jain R, Woo VC.

Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. Epub 2015 Nov 18.

7.

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.

Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB.

Diabetes Care. 2016 Feb;39(2):179-86. doi: 10.2337/dc15-1585.

8.

Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists.

Giorgino F, Bonadonna RC, Gentile S, Vettor R, Pozzilli P.

Diabetes Metab Res Rev. 2016 Sep;32(6):497-511. doi: 10.1002/dmrr.2775. Epub 2016 Mar 30. Review.

9.

Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes.

Lin CH, Hsieh SH, Sun JH, Tsai JS, Huang YY.

Sci Rep. 2015 Nov 26;5:16968. doi: 10.1038/srep16968.

10.
11.

Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.

Tanimoto M, Kanazawa A, Hirose T, Yoshihara T, Kobayashi-Kimura S, Nakanishi R, Tosaka Y, Sasaki-Omote R, Kudo-Fujimaki K, Komiya K, Ikeda F, Someya Y, Mita T, Fujitani Y, Watada H.

J Diabetes Investig. 2015 Sep;6(5):560-6. doi: 10.1111/jdi.12338. Epub 2015 Mar 15.

12.

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.

Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A.

Diabetes Ther. 2015 Sep;6(3):239-56. doi: 10.1007/s13300-015-0127-x. Epub 2015 Aug 14.

13.

Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

Shomali M.

Clin Diabetes. 2014 Jan;32(1):32-43. doi: 10.2337/diaclin.32.1.32. No abstract available.

14.

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.

Tella SH, Rendell MS.

Ther Adv Endocrinol Metab. 2015 Jun;6(3):109-34. doi: 10.1177/2042018815580257. Review.

15.

Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy.

Wiley KC, Akiyode R, Nunlee-Bland G.

Diabetes Spectr. 2015 May;28(2):121-6. doi: 10.2337/diaspect.28.2.121. No abstract available.

16.

Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes.

Lin CH, Lee YS, Huang YY, Hsieh SH, Chen ZS, Tsai CN.

J Diabetes Res. 2015;2015:176949. doi: 10.1155/2015/176949. Epub 2015 Feb 15.

17.

Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients.

Fujisawa K, Yasuda T, Kaneto H, Katakami N, Tsuji M, Kubo F, Sasaki S, Miyashita K, Naka T, Kasami R, Kuroda A, Matsuhisa M, Shimomura I.

J Diabetes Investig. 2014 Sep;5(5):548-53. doi: 10.1111/jdi.12176. Epub 2013 Nov 28.

18.

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.

Singh AK.

Indian J Endocrinol Metab. 2014 Nov;18(6):753-9. doi: 10.4103/2230-8210.141319. Review.

19.

Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.

de Ranitz-Greven WL, Beulens JW, Hoeks LB, Belle-van Meerkerk G, Biesma DH, de Valk HW.

BMC Res Notes. 2014 Aug 29;7:579. doi: 10.1186/1756-0500-7-579.

20.

Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.

Wang T, Gou Z, Wang F, Ma M, Zhai SD.

PLoS One. 2014 Aug 4;9(8):e103798. doi: 10.1371/journal.pone.0103798. eCollection 2014. Review.

Supplemental Content

Support Center